Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation
- PMID: 20214847
- PMCID: PMC3951873
- DOI: 10.1017/S1041610210000244
Predictors of nursing home admission among Alzheimer's disease patients with psychosis and/or agitation
Abstract
Background: The purpose of this study is to identify factors that predict nursing home placement among community-dwelling Alzheimer's disease (AD) patients with psychosis and/or agitation in a randomized clinical trial (ClinicalTrials.gov number, NCT00015548).
Methods: 418 participants with AD enrolled in the Clinical Antipsychotic Trial of Intervention Effectiveness - AD (CATIE-AD) trial of anti-psychotic medications and having no evidence of nursing home use at baseline were followed at 9 months post-random assignment using data provided by caregiver proxy. χ2 tests, t-tests and Cox proportional hazard modeling were used to examine the baseline correlates of nursing home use.
Results: Of outpatients with no prior nursing home use, 15% were placed in a nursing home in the 9 months following baseline, with the average time to placement being 122 days. Bivariate analyses indicate that those with prior outpatient mental health use at study entry were more likely to be admitted; so too were those with worse physical functioning - i.e. lower scores on the AD Cooperative Study Activities of Daily Living Scale (ADCS-ADL), lower utility scores on the Health Utility Index (HUI)-III, and worse cognition on the Mini-mental State Examination. Controlling for other factors, non-Hispanic white race (hazard ratio [HR] = 2.16) and prior mental health use (HR = 1.87) increased the likelihood of admission. Those with higher ADCS-ADL scores were less likely to be placed (HR = 0.97).
Conclusions: Factors leading to nursing home entry among psychotic/agitated AD patients are similar to the general population, though high incidence of nursing home entry highlights the importance of accounting for such utilization in health economic studies of AD outcomes. It also highlights the importance of using information on ADLs and other characteristics to develop profiles identifying those at greater or lesser risk of nursing home entry and, in so doing, inform population planning associated with AD and identification of those patients and caregivers who might benefit most from interventions to prevent eventual placement.
Similar articles
-
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease.Am J Psychiatry. 2013 Sep;170(9):1051-8. doi: 10.1176/appi.ajp.2013.12081046. Am J Psychiatry. 2013. PMID: 23896958 Free PMC article.
-
Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.Int J Geriatr Psychiatry. 2017 Dec;32(12):1264-1271. doi: 10.1002/gps.4607. Epub 2016 Oct 7. Int J Geriatr Psychiatry. 2017. PMID: 27714849
-
Assessing the relationship between health utilities, quality of life, and health services use in Alzheimer's disease.Int J Geriatr Psychiatry. 2009 Jan;24(1):96-105. doi: 10.1002/gps.2160. Int J Geriatr Psychiatry. 2009. PMID: 19016254 Clinical Trial.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Psychosis of Alzheimer's disease: clinical characteristics and history.J Psychiatr Res. 2004 Jan;38(1):105-11. doi: 10.1016/s0022-3956(03)00092-x. J Psychiatr Res. 2004. PMID: 14690773 Review.
Cited by
-
Low Dose Lithium Treatment of Behavioral Complications in Alzheimer's Disease: Lit-AD Randomized Clinical Trial.Am J Geriatr Psychiatry. 2022 Jan;30(1):32-42. doi: 10.1016/j.jagp.2021.04.014. Epub 2021 May 12. Am J Geriatr Psychiatry. 2022. PMID: 34059401 Free PMC article. Clinical Trial.
-
Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.JAMA. 2014 Jan 1;311(1):33-44. doi: 10.1001/jama.2013.282834. JAMA. 2014. PMID: 24381967 Free PMC article. Clinical Trial.
-
Testing Tele-Savvy: Protocol for a randomized controlled trial.Res Nurs Health. 2018 Apr;41(2):107-120. doi: 10.1002/nur.21859. Epub 2018 Feb 5. Res Nurs Health. 2018. PMID: 29399825 Free PMC article. Clinical Trial.
-
Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13. Alzheimers Dement. 2019. PMID: 30555031 Free PMC article.
-
Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial.Contemp Clin Trials Commun. 2019 May 23;15:100385. doi: 10.1016/j.conctc.2019.100385. eCollection 2019 Sep. Contemp Clin Trials Commun. 2019. PMID: 31338476 Free PMC article.
References
-
- AD2000 Collaborate Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial. The Lancet. 2004;363:2105–2115. - PubMed
-
- Alzheimer's Association . Alzheimer's Disease Facts and Figures. Alzheimer's Association; Chicago, Illinois: 2009.
-
- Anderson R. Revisiting the behavior model and access to care: Does it matter? Journal of Health and Social Behavior. 1995;36:1–10. - PubMed
-
- Beller SA, Overall JE. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: II. Representative profile patterns. Journal of Gerontology. 1984;39:194–200. - PubMed
-
- Blaum CS, Ofstedal MB, Liang J. Low cognitive performance, comorbid disease, and task-specific disability: Findings from a nationally representative survey. Journal of Gerontology: Medical Sciences. 2002;57A:M523–M531. - PubMed